The IRDye800 conjugated with the clinically approved monoclonal antibody anti-epidermal growth factor EGFR Cetuximab (cetuximab-IRDye800) has shown promising results as a specific tracker in other cancer types (i.e., brain, pancreas, head, and neck) [18–20]. Here, EGF is linked to cancer.